Evidence map›Paper›PMID 34444960›Full record

ArticleNutrients2021

Hesperidin Is a Potential Inhibitor against SARS-CoV-2 Infection.

Fang-Ju Cheng, Thanh-Kieu Huynh, Chia-Shin Yang, Dai-Wei Hu, Yi-Cheng Shen, Chih-Yen Tu, Yang-Chang Wu, Chih-Hsin Tang, Wei-Chien Huang, Yeh Chen and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 124 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Fang-Ju ChengDrug Development Center, China Medical University, Taichung 404, Taiwan.
Thanh-Kieu HuynhGraduate Institute of Biomedical Science, China Medical University, Taichung 404, Taiwan.
Chia-Shin YangInstitute of New Drug Development, China Medical University, Taichung 404, Taiwan.
Dai-Wei HuGraduate Institute of Biomedical Science, China Medical University, Taichung 404, Taiwan.
Yi-Cheng ShenGraduate Institute of Biomedical Science, China Medical University, Taichung 404, Taiwan.
Chih-Yen TuDepartment of Internal Medicine, Division of Pulmonary and Critical Care Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Yang-Chang WuChinese Medicine Research and Development Center, China Medical University Hospital, Taichung 404, Taiwan.
Chih-Hsin TangGraduate Institute of Biomedical Science, China Medical University, Taichung 404, Taiwan.ORCID 0000-0002-7113-8352
Wei-Chien HuangDrug Development Center, China Medical University, Taichung 404, Taiwan.ORCID 0000-0001-6467-8716
Yeh ChenDrug Development Center, China Medical University, Taichung 404, Taiwan.
Chien-Yi HoDepartment of Biomedical Imaging and Radiological Science, China Medical University, Taichung 404, Taiwan.
China Medical University · TWAsia University · TW

Funding

China Medical University Hospital DMR-109-212China Medical University Hospital DMR-109-213China Medical University, Taiwan CMU106-ASIA-18China Medical University, Taiwan CMU107-TU-06Ministry of Science and Technology, Taiwan MOST 109-2320-B-039-014
6 · The paper itself

Abstract

Hesperidin (HD) is a common flavanone glycoside isolated from citrus fruits and possesses great potential for cardiovascular protection. Hesperetin (HT) is an aglycone metabolite of HD with high bioavailability. Through the docking simulation, HD and HT have shown their potential to bind to two cellular proteins: transmembrane serine protease 2 (TMPRSS2) and angiotensin-converting enzyme 2 (ACE2), which are required for the cellular entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our results further found that HT and HD suppressed the infection of VeroE6 cells using lentiviral-based pseudo-particles with wild types and variants of SARS-CoV-2 with spike (S) proteins, by blocking the interaction between the S protein and cellular receptor ACE2 and reducing ACE2 and TMPRSS2 expression. In summary, hesperidin is a potential TMPRSS2 inhibitor for the reduction of the SARS-CoV-2 infection.

Indexed as

COVID-19 Drug TreatmentAngiotensin-Converting Enzyme 2AnimalsCell Line, TumorChlorocebus aethiopsCoronavirus Papain-Like ProteasesCOVID-19HesperidinHumansMolecular Docking SimulationSARS-CoV-2Serine EndopeptidasesSpike Glycoprotein, CoronavirusVero CellsACE2 protein, humanAngiotensin-Converting Enzyme 2Coronavirus Papain-Like ProteaseshesperetinHesperidinpapain-like protease, SARS-CoV-2Serine EndopeptidasesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2TMPRSS2 protein, human501Y.v2ACE2D614GhesperidinSARS-CoV-2TMPRSS2

Identifiers

PMID34444960
PMCPMC8401008
OpenAlexW3194955921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.